Hikal Reports Flat Q3 FY24-25 Results Amid Rising Costs and Evaluation Adjustments

Hikal, a small-cap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a flat financial performance for Q3 FY24-25, with a notable adjustment in its evaluation, as the score has shifted to -2 from -1 over the past three months.
Analyzing the financials, Hikal has demonstrated a commendable debt-equity ratio of 0.64 times, marking the lowest level in the last five half-yearly periods. This suggests a strategic reduction in borrowing relative to equity capital, which may reflect prudent financial management.

However, the company faces challenges as evidenced by its profit before tax (PBT), which has recorded a decline of 18.5% compared to the average of the previous four quarters. Additionally, the profit after tax (PAT) has also shown a decrease of 6.3% over the same period. Rising interest costs, which have increased by 34.57% over the preceding nine months, further complicate the financial landscape. On a positive note, non-operating income has reached its highest level in five quarters, although the sustainability of this income remains uncertain.

For more insights on Hikal's financial trends and evaluation changes, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.